

# **Pharmacy Drug Policy & Procedure**

Policy Name:	Nexletol (bempedoic acid) and Nexlizet (bempedoic acid-ezetimibe)	Policy #:	2758P
--------------	---	-----------	-------

## **Purpose of the Policy**

The purpose of this policy is to define the criteria for coverage of Nexletol and Nexlizet.

# **Statement of the Policy**

Health Alliance Medical Plans will approve the use of Nexletol or Nexlizet when the following criteria have been met.

## Criteria

## 1. Coverage Criteria

- 1.1 Diagnosis of one of the following:
  - Established atherosclerotic cardiovascular disease (ASCVD) or high risk for a cardiovascular event but without established heart disease
  - Heterozygous familial hypercholesterolemia (high cholesterol)
- 1.2 Age 18 years or older
- 1.3 Inability to achieve low-density lipoprotein cholesterol (LDL-C) goals on maximally tolerated statin therapy (such as atorvastatin)

### 2. Exclusion Criteria

2.1 Nexletol will not be covered in combination with PCSK9 therapy such as Repatha or Praluent

#### 3. Approval Period

- 3.1 Initial: 12 months
- 3.2 Reauthorization: 12 months with documented clinical benefit

5.2 Reauthorization: 12 months with documented chinical benefit				
CPT Codes				
HCPCS Codes				

## References

- 1. Nexletol (bempedoic acid) [prescribing information]. Ann Arbor, MI: Esperion Therapeutics Inc; March 2024.
- 2. Nexlizet (bempedoic acid and ezetimibe) [prescribing information]. Ann Arbor, MI: Esperion Therapeutics Inc; March 2024.
- 3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American

- College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):e285- e350.
- 4. American College of Cardiology Solution Set Oversight Committee 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. J Am Coll Cardiol. 2022 Oct 4;80(14):1366-1418.

Created Date: 06/03/20 Effective Date: 06/03/20 Posted to Website: 01/01/22 Revision Date: 06/05/24

## **DISCLAIMER**

This Medical Policy has been developed as a guide for determining medical necessity. The process of medical necessity review also entails review of the most recent literature and physician review. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Health Alliance encourages input from providers when developing and implementing medical policies. Benefit determinations are based on applicable contract language in the member's Policy/ Subscription Certificate/ Summary Plan Description. This Medical Policy does not guarantee coverage. There may be a delay between the revision of this policy and the posting on the web. Please contact the Health Alliance Customer Service Department at 1-800-851-3379 for verification of coverage.